Viking Therapeutics, Inc. 10-Q

Item 5. Other Information Insider Adoption or Termination of Trading Arrangements: During the fiscal quarter ended March 31, 2026, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K, except as described in the table below: Name & Title Date Adopted Type of Plan Aggregate Number of Shares of Common Stock to be Sold Pursuant to Trading Arrangement Duration Brian Lian , Ph.D., President, Chief Executive Officer and Director January 15, 2026 Rule 10b5-1 trading arrangement 365,000 December 31, 2026 (1) (1) The trading arrangement permits transactions through and including the earlier to occur of (a) the date that all shares subject to the trading arrangement have been sold and (b) the date listed in the table. Chief Operating Officer As previously disclosed, on February 10, 2026, Marianne Mancini provided us with notice that she would be retiring and therefore resigning from her role as our Chief Operating Officer, effective April 30, 2026. On April 27, 2026, Ms. Mancini notified us of her decision not to retire and to rescind her resignation. As a result, Ms. Mancini will continue to serve as our Chief Operating Officer under the previously existing employment agreement by and between Ms. Mancini and us, dated May 21, 2015, as described in our Definitive Proxy Statement for our 2026 Annual Meeting of Stockholders filed with the Securities and Exchange Commission on April 1, 2026 (the “Proxy Statement”). The information with respect to Ms. Mancini as required by Items 401(b), (d), (e) and Item 404(a) of Regulation S-K is set forth in the Proxy Statement and is hereby incorporated by reference herein. Purported Termination of TR-Beta Program License On April 24, 2026, Ligand notified us that it is purporting to terminate Ligand’s license of the TR-Beta Program to us under the Master License Agreement, effective as of May 4, 2026. The TR-Beta Program includes our VK2809 product candidate. We believe Ligand has no right under the Master License Agreement to terminate the license with respect to the TR-Beta Program and will vigorously defend and enforce our rights under the Master License Agreement against any attempt to violate, misappropriate or infringe those rights with respect to any of our licensed programs. 67 Item 6. Exhibits Exhibit Number Description Registrant’s Form Date Filed with the SEC Exhibit Number 3.1 Amended and Restated Certificate of Incorporation. S-1 7/1/2014 3.3 3.2 Amended and Restated Bylaws of Viking Therapeutics, Inc., effective as of May 9, 2023. 8-K 5/11/2023 3.1 4.1 Form of Common Stock Certificate. S-1 7/1/2014 4.1 10.1# Employment Agreement, effective January 12, 2026, by and between Viking Therapeutics, Inc. and Neil Aubuchon. 31.1 Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934. 31.2 Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities Exchange Act of 1934. 32.1 Certification of the Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. 101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. 101.SCH Inline XBRL Taxonomy Extension Schema Document. 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document. 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document. 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document. 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document. 104 Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). ## Indicates management contract or compensatory plan or arrangement. Attached as Exhibit 101 to this report are the following formatted in iXBRL (Inline Extensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025, (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2026 and 2025, (iii) Condensed Consolidated Statements of Stockholders’ Equity for the three months ended March 31, 2026 and 2025, (iv) Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2026 and 2025, and (v) Notes to Condensed Consolidated Financial Statements. 68 SIGNAT URES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Viking Therapeutics, Inc. Date: April 29, 2026 By: /s/ Brian Lian, Ph.D. Brian Lian, Ph.D. President, Chief Executive Officer and Director (Principal Executive Officer) Date: April 29, 2026 By: /s/ Greg Zante Greg Zante Chief Financial Officer (Principal Accounting and Financial Officer) 69